Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms

Manop Pithukpakorn1
Tiwat Tiwawanwong2
Yupaporn Lalerd3
Anunchai Assawamakin3,4
Nalinee Premasathian2
Adis Tasanarong5
Wanna Thongnoppakhun3
Attapong Vongwiwatana2

1Division of Medical Genetics, 
2Division of Nephrology, Department of Medicine, 
3Division of Molecular Genetics, Department of Research and Development, Faculty of Medicine Siriraj Hospital, 
4Department of Pharmacology, Faculty of Pharmacy, Mahidol University, 
5Department of Medicine, Faculty of Medicine, Thammasat University, Bangkok, Thailand

Background: Despite use of a lower mycophenolate dose in Thai kidney transplant patients, acceptable graft and patient outcomes can be achieved. We therefore examined the pharmacokinetics of mycophenolic acid (MPA) by area under the curve (AUC) and investigated genetic contribution in mycophenolate metabolism in this population.

Methods: Kidney transplant recipients with stable graft function who were receiving mycophenolate mofetil 1,000 mg/d in combination with either cyclosporine or tacrolimus, and prednisolone were studied. The MPA concentration was measured by fluorescence polarization immunoassay (FPIA), at predose and 1, 1.5, 2, 4, 6, 8, 10, and 12 hours after dosing. Genetic polymorphisms in UGT1A8, UGT1A9, and UGT2B7 were examined by denaturing high-performance liquid chromatography (DHPLC)-based single-base extension (SBE) analysis.

Results: A total 138 patients were included in study. The mean AUC was 39.49 mg-h/L (28.39–89.58 mg-h/L), which was in the therapeutic range. The correlation between the predose MPA concentration and AUC was poor. The mean AUC in the tacrolimus group was higher than that in the cyclosporine group. Polymorphisms in UGT2B7 showed significant association with AUC.

Conclusion: Most of our patients with reduced mycophenolate dose had the AUC within the therapeutic range. Genetic polymorphisms in UGT2B7 may play a role in MPA metabolism in Thai kidney transplant patients.

Keywords: UGT, MPA, pharmacokinetic, immunosuppressive

Introduction
Mycophenolate is a highly effective immunosuppressive drug that has been used to prevent rejection in organ transplant recipients. The active metabolite, mycophenolic acid (MPA), acts by inhibiting inosine monophosphate dehydrogenase enzyme (IMPDH), which mediates the synthesis of purine and therefore controls lymphocyte proliferation. Mycophenolate was formulated as prodrugs, called mycophenolate mofetil (MMF), and as a salt form, mycophenolate sodium (MPS). The current recommended doses in adults is 1,000 mg twice daily for MMF and 720 mg twice daily for MPS. Adjustment for body weight is not necessary. The area under the curve (AUC) of MPA as MMF and MPS at these doses was found to be equivalent. Previous study has shown that an appropriate AUC at 0–12 hours after drug administration, between 30–60 mg-h/L, was associated with significant decrease in acute graft rejection in kidney transplant patients.

MPA is primarily metabolized by the liver, through glucuronidation. Several uridine glucuronosyltransferases (UGTs) are involved in the metabolism process.
All patients visited the clinic in the morning and stayed for 12 hours, during the study. Blood samples from the patients were collected at time 0 (predose) and at 1, 1.5, 2, 4, 6, 8, 10, and 12 hours after oral MMF or MPS was given. Genomic DNA from each patient was extracted from the leftover cellular portion from blood samples and used for pharmacogenetic study. MPA measurement from collected serum was performed at the certified clinical laboratory, by fluorescence polarization immunoassay (FPIA), with a Cobas Integra® 400 system (F Hoffman-La Roche Ltd, Basel, Switzerland). The system yielded excellent correlation with liquid chromatography with tandem mass spectrometry (LC-MS/MS) technique.10

For pharmacogenetic testing, DNA regions of interest were amplified from genomic DNA collected as described above, with multiplex polymerase chain reaction (PCR) to create six distinct fragments. Investigation for six well-established polymorphisms of the UGT1A8, 1A9, and 2B7 was performed by multiplex PCR and denaturing high-performance liquid chromatography (DHPLC)-based single-base extension (SBE) analysis. The SBE products were analyzed on a fully denaturing mode of the WAVE™ DHPLC system equipped with an OLIGOSep™ cartridge (catalog number NUC-99-3550; Transgenomic, Omaha, NE, USA).

Analyses of clinical and pharmacokinetic data were done by SPSS for Windows, version 16.0. Spearman’s correlation was used for correlation analysis between pharmacokinetic parameters and clinical data. Pharmacogenetic data were tested for deviation from Hardy–Weinberg equilibrium. Based on the previous data that AUC between 30–60 mg-h/L was associated with reduced rejection rate, individuals with AUC at 30 mg-h/L or higher were defined as the case group and those with AUC below 30 mg-h/L were defined as the control group. The degree of linkage disequilibrium between loci was measured using Lewontin’s D′ and r², using the JLIN software program.11 Test for association was done with analysis of allele frequency difference, heterozygous states, homozygous states, and allele positivity, using Pearson’s goodness-to-fit chi-square test. The Bonferroni correction (P<0.05 divided by the number of single nucleotide polymorphisms analyzed) was used to account for multiple testing.

Results
Clinical and AUC data
Of 138 patients, 76 (55.1%) patients underwent living-related kidney transplantation, while 62 (44.9%) patients underwent deceased-donor kidney transplantation. Mean serum
creatinine was 1.35±0.41 mg/dL. All patients received half of the recommended dose of mycophenolate, by either 1,000 mg of MMF or 720 mg of MPS daily (76.8% and 23.2%, respectively), as our standard protocol. Further demographic data are demonstrated in Table 1.

For patients receiving MMF, MPA concentration rose rapidly after oral administration, and peak level was reached at 1 hour. The concentration decreased gradually after 2 hours and became stable after 6 hours. The concentration curve from each patient showed a very similar pattern without delayed peak level. In contrast, patients receiving MPS showed a sustained level of MPA concentration after oral administration, with no peak level throughout the monitoring period. The mean AUC was 39.49±13.28 (28.39–89.58) mg-h/L. We also compared AUC between patients who were on different calcineurin inhibitors. The mean AUC in the tacrolimus group was higher than that in the cyclosporine group, but there was no statistical difference (41.27±15.82 vs 35.69±13.67 mg-h/L) (P=0.1). The patients who were on MMF had similar AUC to the patients with equivalent dose of MPS. The correlation between the predose MPA concentration and AUC was poor (r²=0.255).

**Pharmacogenetic data**

Genotype data on selected polymorphisms showed that for **UGT1A8**, S43L (rs372427845), H53N (rs45504099), A231T (rs72551325), T240A (rs72551326), and C277Y (rs17863762); and for **UGT1A9**, -2152C/T (rs17868320) and -275 T/A (rs6714486) were all homozygous, in both patients with AUC above 30 mg-h/L (case group) and below 30 mg-h/L (control group). We found that for **UGT2B7**, -824G/A (rs7438135) and H268Y (rs7439366); and for **UGT1A8**, A173G (rs1042597) showed heterozygosity on both loci. These alleles were in Hardy–Weinberg equilibrium, for both case and control groups. Tests for association showed that for **UGT2B7**, -824G/A and H268Y both had statistically significant allele frequency differences between the case and control groups. In addition, -824G/A and H268Y were highly linked (D'= 1) (r²=0.966). For **UGT2B7** at position -824, the common odds ratio of having G allele in case group was 0.604 when compared with A allele (P=0.03674). The presence of G allele (G/G or G/A) had odds ratio of 0.461 compared with the absence of G allele (A/A). Heterozygous G/A at this position also had significant odds of 0.451 when compared with homozygous A/A. Meanwhile, for **UGT2B7** at position 268, the common odds ratio of having a C (Y) allele in the case group was 0.557 compared with the T (H) allele (P=0.01858). The presence of C allele (C/C: YY or C/T: HY) had odds ratio of 0.433 compared with the absence of C allele (T/T: HH). Heterozygous C/T (HY) at this position also had significant odds of 0.435 compared with homozygous C/C (HH). After Bonferroni correction was used, **UGT2B7** polymorphism remained statistically significant. Among the 138 patients who participated in the study, we found that patients who carried G allele at position -824 also had a C (Y) allele at position 268, and patients who carried C allele at position -824 also had a T (H) allele at position 268 of **UGT2B7**. In contrast, we did not see significant association on **UGT1A8** at position A173G and AUC (Table 2). Since two alleles of **UGT2B7** were linked, we chose to examine the correlation between AUC in percentile and the **UGT2B7** H268Y allele. We found that patients who were HY heterozygous had lower average AUC (38.5 mg-h/L) than did patients who were HH homozygous (44.18 mg-h/L). The AUC percentile comparison found the highest frequency of HY heterozygote was in the fourth decile (30–40 mg-h/L), while the highest frequency of the HH homozygote was in the fifth decile (40–50 mg-h/L) (Figure 1A and B).

**Table 1** Demographic data of 138 patients who underwent pharmacokinetic study

| Characteristics       | Value (% or range) |
|-----------------------|--------------------|
| Number of patients    | 138                |
| Ethnicity: Thai       | 138 (100%)         |
| Sex (n)               |                    |
| Male                  | 83 (60.1%)         |
| Female                | 55 (39.9%)         |
| Age (years)           | 42±11 (31–53)      |
| Body weight (kg)      | 64±13 (51–77)      |
| Body surface area (m²)| 1.70±0.2 (1.5–1.9) |
| Donor source (n)      |                    |
| Deceased donor        | 62 (44.9%)         |
| Living-related        | 76 (55.1%)         |
| CNI (n)               |                    |
| CsA                   | 75 (54.3%)         |
| TAC                   | 63 (45.7%)         |
| Serum Cr (mg/dL)      | 1.35±0.41          |
| Calculated Ccr (mL/min/1.73 m²) | 65.08±18.15 |
| Serum albumin (g/dL)  | 4.46±0.3           |
| WBC (cell/mm³)        | 7.985±2.877        |
| AST (IU/L)            | 21.4±7.49          |
| ALT (IU/L)            | 23.51±3.16         |
| Dose of MPA (n)       |                    |
| MMF 1,000 mg/d        | 106 (76.8%)        |
| MPS 720 mg/d          | 32 (23.2%)         |
| CsA dose (mg/d)       | 134.64 (50–350)    |
| TAC dose (mg/d)       | 4.2 (1–14.5)       |
| Prednisolone dose (mg/d) | 5.11 (2.5–15) |

**Abbreviations:** ALT, alanine transaminase; AST, aspartate transaminase; Ccr, creatinine clearance; CNI, calcineurin inhibitor; Cr, creatinine; CsA, cyclosporine; MMF, mycophenolate mofetil; MPA, mycophenolic acid; MPS, extended release form of mycophenolate sodium; TAC, tacrolimus; WBC, white blood cells.
**Table 2** Test for association between polymorphisms and AUC

| Polymorphism   | Allele frequency of control group* | Allele frequency of case group* | Allele frequency difference | Heterozygous vs homozygous | Common odds ratio |
|----------------|-----------------------------------|---------------------------------|----------------------------|---------------------------|------------------|
| UGT2B7 -824G/A | GG =3 (5.14)                      | GG =4 (3.81)                    | OR =1.699 (P=0.04389)      | OR =0.451 (P=0.01968)    | OR =0.604 (P=0.03674) |
| UGT2B7 H268Y (T/C) | TT =22 (23.78)                 | TT =53 (52.81)                    | OR =1.820 (P=0.02190)      | OR =0.435 (P=0.01535)    | OR =0.557 (P=0.01858) |
| UGT1A8 A173G (C/G) | CC =20 (18.72)                  | CC =24 (23.82)                    | OR =1.277 (P=0.29474)      | OR =1.509 (P=0.27077)    | OR =1.247 (P=0.30744) |

Note: *Expected allele frequencies in Hardy–Weinberg equilibrium were shown in parenthesis.

Abbreviations: AUC, area under the curve; CI, confidence interval; OR, odds ratio.

**Discussion**

Our study was the first report of pharmacokinetic and pharmacogenetic studies in Thai kidney transplant patients who received reduced dose of mycophenolate. We demonstrated that the majority of patients had adequate AUC level despite that all patients received smaller dose of mycophenolate than the Caucasian population. These results were similar to other reports of higher AUC among Asian kidney transplant individuals who were on mycophenolate, compared with Western patients.6,7 These findings also support our clinical observation that many Thai kidney transplant patients experienced high incidence of mycophenolate-related adverse reaction with full
dose and that most of the Thai transplanted patients at Siriraj Organ Transplant Center were able to tolerate reduced myco-phenolate dosage with acceptable graft survival outcome and acute rejection rate. A recent study in Japanese renal transplant patients also found that the majority of patients who were using a MMF plus cyclosporine-based regimen were unable to tolerate the original dosage of 2 g/day due to adverse effects and subsequently reduced to a mean dosage of 1.24 g/day.11

There were previous studies on the relationship between MPA pharmacokinetics and graft rejection, and on adverse effects in various organ transplant cohorts. Some results showed that high MPA level (peak or trough) or high AUC were associated with increased risk of side effects, while other results did not.12-15 A systematic review published in 2008 showed that MPA AUC and total dose had good correlation with risk of acute graft rejection and that free MPA level may better predict toxicity.16 The study by Yau et al brought an interesting concept that current recommended fixed dose should not be ideal for all patients.17 The authors concluded that the body weight-adjusted MMF dosage tended to be lower than that reported from the Western population. Yau et al further concluded that the 12 mg/kg twice daily dose of MMF (24 mg/kg/day) should provide adequate AUC for Asian patients. However, whether there are ethnic differences in mycophenolate disposition in the Asian population needs further investigation. Studies to determine whether genetic differences in the drug-metabolizing enzymes for MPA could be a contributing factor were suggested. Our finding confirmed the conclusion of Yau et al that Asian patients required lower MMF dosage than do Caucasian patients. The range of body weight-adjusted MMF dosages in our study was 13–19.6 mg/kg/day. Our study showed that polymorphisms in UGT2B7 – a drug metabolizing enzyme gene – were associated with MPA AUC. As expected, we did not find the difference in AUC between the suggested doses of MMF and MPS, thus supported the bioequivalence of these two preparations. It is of interest to observe that patients treated with tacrolimus tend to have lower AUC than those with tacrolimus. It has been known that enterohepatic recirculation of MPA involves excretion of MPAG into the intestinal lumen through the biliary system. Multidrug resistance-associated protein 2 (MRP2) at the apical surface of hepatocytes plays an active role in MPAG excretion. Inactive MPAG is then deconjugated by intestinal bacteria to become active MPA and is absorbed into circulation. The enterohepatic recirculation was estimated to contribute about 40% of the total AUC. Cyclosporine is an inhibitor of MRP2 at the apical surface of hepatocytes and may cause an AUC reduction in those patients who are on cyclosporine. The results of our study indicated that most Thai kidney transplant patients achieve an adequate AUC value even though lower dose of mycophenolate was administered. Similar findings from several populations suggested that a genetic factor may play role in difference in MPA metabolism.18-20 We were interested in UGT1A8, I49, and 2B7 polymorphisms, due to their involvement in the MPA metabolic pathway. Our results showed that polymorphisms at position -824 and 268 of UGT2B7 were associated with the AUC of MPA. Because both alleles were linked, the data did not allow us to conclude the real contribution from each allele. Study of UGT2B7 glucuronidation in human hepatocytes showed that T/T (HH) polymorphism had modestly lower activity than C/C (YY) polymorphism. Though H268Y polymorphism was sufficient to affect MPA kinetics,20 there was evidence that promoter polymorphism may also have influence on MPA metabolism, in addition to H268Y allele.21 Lower enzyme activity gives rise to slower conversion from MPA to MPAG. This result may explain the lower AUC in patients who carried the HY allele, when compared with HH allele. No association was demonstrated in the YY allele group, due to inadequate sample size. However, the present study had several limitations. First, the purpose of this study was mainly to demonstrate that majority of Thai kidney transplanted patients who received half of the recommended fixed-dose regimen without rejection could achieve an AUC target above 30 mg-h/L. Though this result supported the fact that Thai patients, similar to other Asian cohorts, require a smaller mycophenolate dose than Caucasian patients, we could not conclude that the low dose regimen is suitable for long-term immunosuppression since the outcomes on graft survival, development of donor-specific antibody, and other clinical parameters require ongoing follow-up study of this cohort. Second, we did not include all genetic polymorphisms that could affect the pharmacokinetics and pharmacodynamics of MPA. Furthermore, no significant association in selected UGT1A8 and I49 polymorphisms was observed due to uninformative alleles (for UGT1A8, these were S43L, H53N, A231T, T240A, and C277Y; and for UGT1A9, these were -2152C/T and -275 T/A). The lack of informative alleles did not allow us to observe additive effects of several UGTs on MPA metabolism. We also did not observe an association in polymorphism at position 173 of UGT1A8. One explanation is that in vitro study revealed no significant effect of UGT1A8 activity for the codon 173 variation because MPA metabolism involves many UGTs as well as other cellular transporters, such as ABC2 (MRP2), ABCG2, and SLCO proteins.22 As expected, we detected moderate contribution in UGT2B7 polymorphisms. Other studies on the effect of UGT polymorphisms and MPA pharmacokinetics have previously
been done and revealed similar results; however these were mainly performed in healthy individuals using a single dose of MMF.20,21 Our study in transplanted recipients should better represent real clinical scenarios in which patients have regular and concurrent use of multiple immunosuppressive drugs.

In conclusion, the majority of Thai patients could maintain adequate AUC despite a lower mycophenolate dosage than recommendation. We also demonstrated the significant association between UGT2B7 polymorphisms and AUC level, suggesting the role of genetic polymorphisms in MPA metabolism and AUC, in our kidney transplant patients. However, further investigation of other polymorphisms in UGTs and other transporter genes would be crucial to elucidate a better picture of pharmacogenetic roles of MPA metabolism.

Author contributions
Manop Pithupakorn participated in research design, data analysis, and writing of the manuscript. Tiwat Tiwawanwong, Yupaporn Lalerd, and Nalinee Premasathian performed data collection and data analysis. Anunchai Assawamakin performed data analysis. Adis Tasanarong participated in research design. Wanna Thongnoppakhun participated in research design and data analysis. Attapon Vongwiwatana participated in research design, data collection, data analysis, and writing of the manuscript. All authors participated in manuscript revision, ensured data integrity and approved the final version of the manuscript.

Acknowledgments
We wish to thank all the patients for their cooperation and participation in this study.

This work was supported by funding from Siriraj Research Development Grant, Siriraj Kidney Transplant Grant, Siriraj Core Research Facility, and the Thai Transplantation Society.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60(3):225–232.
2. Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant. 200519(2):199–206.
3. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13–58.
4. Yang JW, Lee PH, Hutchinson IV, Pravica V, Shah T, Min DI. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther Drug Monit. 2009;31(5):542–548.
5. Betónico GN, Abbud-Filho M, Goloni-Bertollo EM, et al. Influence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side effects in kidney transplant patients. Transplant Proc. 2008;40(3):706–710.
6. Suhail SM, Vathsala A, Lou HW, Woo KT. Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients. Transplant Proc. 2000;32(7):1757–1758.
7. Zhou PJ, Xu D, Yu ZC, Wang XH, Shao K, Zhao JP. Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients. Clin Pharmacokinet. 2007;46(5):389–401.
8. Krämer BK, Del Castillo D, Margeiret R, et al; European Tacrolimus versus Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Nephrol Dial Transplant. 2008;23(7):2386–2392.
9. Jirasiritham S, Sumethkul V, Movichak V, Na-Bangchang K. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. Transplant Proc. 2004;36(7):2076–2078.
10. van Gelder T, Donk I, Engelmayr J, et al. Clinical utility of a new enzymatic assay for determination of mycophenolic acid in combination with an optimized LC-MS/MS method. Ther Drug Monit. 2009;31(2):218–223.
11. Carter KW, McCaskie PA, Palmer LJ. JLIN: a java based linkage disequilibrium plotter. BMC Bioinformatics. 2006;7:60.
12. Takahashi K, Uchida K, Yoshimura N, et al. Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results. Transplant Res. 2013;2(1):14.
13. Kaye DR, Claes K, Evenepoel P, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol. 2003;43(8):866–880.
14. Figurski MJ, Pawiński T, Goldberg LR, et al. Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. Ann Transplant. 2012;17(1):68–78.
15. Mourad M, Malaise J, Chaïb Edourd D, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem. 2001;47(1):88–94.
16. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008;85(12):1675–1685.
17. Yau WP, Vathsala A, Lou HX, Chan E. Is a standard fixed dose of mycophenolate mofetil ideal for all patients? Nephrol Dial Transplant. 2007;22(12):3638–3645.
18. Bernard O, Tjojic J, Journault K, Perusse L, Guillemette C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos. 2006;34(9):1539–1545.
19. Kagaya H, Inoue K, Miura M, et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007;63(3):279–288.
20. Lévesque E, Delage R, Benoit-Biancamano MO, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther. 2007;81(3):392–400.
21. Duguay Y, Bkár C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. *Clin Pharmacol Ther.* 2004;75(3):223–233.

22. Miura M, Satoh S, Inoue K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. *Eur J Clin Pharmacol.* 2007;63(12):1161–1169.

23. Guo D, Pang LF, Han Y, et al. Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers. *Eur J Clin Pharmacol.* 2013;69(4):843–849.